for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Ovid Therapeutics Inc

OVID.OQ

Latest Trade

2.32USD

Change

-0.08(-3.14%)

Volume

20,055

Today's Range

2.31

 - 

2.43

52 Week Range

1.55

 - 

6.60

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
2.39
Open
2.40
Volume
20,055
3M AVG Volume
10.54
Today's High
2.43
Today's Low
2.31
52 Week High
6.60
52 Week Low
1.55
Shares Out (MIL)
47.69
Market Cap (MIL)
113.99
Forward P/E
-1.59
Dividend (Yield %)
--

Latest Developments

More

Ovid Therapeutics Announces Pricing Of $32.5 Mln Of Securities In Concurrent Public Offerings Of Common Stock And Preferred Stock

Ovid Therapeutics Q2 Loss Per Share $0.34

Ovid Therapeutics Initiates Late-Stage Trial In Angelman Syndrome

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Ovid Therapeutics Inc

Ovid Therapeutics Inc. (Ovid) is a biopharmaceutical company. The Company is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist. Ovid is developing OV101 for use in both Angelman syndrome and Fragile X syndrome to potentially restore tonic inhibition and relieve several of the symptoms of these disorders. Ovid has initiated the Phase II STARS trial of OV101 in adults with Angelman syndrome and a Phase I trial in adolescents with Angelman syndrome or Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies.

Industry

Biotechnology & Drugs

Contact Info

1460 Broadway Ste 15044

+1.646.6617661

http://www.ovidrx.com/

Executive Leadership

Jeremy Max Levin

Chairman of the Board, Chief Executive Officer

Thomas M. Perone

Senior Vice President, General Counsel and Corporate Secretary

Dirk Haasner

Senior Vice President - Global Regulatory Affairs

Timothy G. Daly

Vice President - Finance, Corporate Controller

Amit Rakhit

Chief Medical and Portfolio Management Officer

Key Stats

1.63 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2017

-3.350

2018

-2.110

2019(E)

-1.500
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
2.04
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-98.69
Return on Equity (TTM)
-85.36

Latest News

Latest News

BRIEF-Ovid Therapeutics Reports Q1 Loss Per Share Of $0.54

* OVID THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND CORPORATE PROGRESS

BRIEF-Ovid Therapeutics Reports Q4 Loss Per Share $0.45

* OVID THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND CORPORATE PROGRESS

BRIEF-Ovid Therapeutics Announces OV101 Granted Fast Track Designation By FDA For Fragile X Syndrome Treatment

* OVID THERAPEUTICS ANNOUNCES OV101 GRANTED FAST TRACK DESIGNATION BY U.S. FDA FOR TREATMENT OF FRAGILE X SYNDROME

BRIEF-Ovid Therapeutics Announces TAK-935/OV935 Granted Orphan Drug Designation By U.S. FDA For Treatment Of Lennox-Gastaut Syndrome

* OVID THERAPEUTICS ANNOUNCES TAK-935/OV935 GRANTED ORPHAN DRUG DESIGNATION BY U.S. FDA FOR TREATMENT OF LENNOX-GASTAUT SYNDROME

BRIEF-Ovid Therapeutics Announces OV101 Granted Fast Track Designation By U.S. FDA For Treatment Of Angelman Syndrome

* OVID THERAPEUTICS ANNOUNCES OV101 GRANTED FAST TRACK DESIGNATION BY U.S. FDA FOR TREATMENT OF ANGELMAN SYNDROME

BRIEF-Ovid Therapeutics Announces TAK-935/Ov935 Has Received Orphan Drug Designation From U.S. FDA For Treatment Of Dravet Syndrome

* OVID THERAPEUTICS ANNOUNCES TAK-935/OV935 HAS RECEIVED ORPHAN DRUG DESIGNATION FROM U.S. FDA FOR TREATMENT OF DRAVET SYNDROME

BRIEF-Ovid Therapeutics Announces OV101 Shows Comparable Pk Profile In Phase 1 Study Of Adolescent Patients

* OVID THERAPEUTICS ANNOUNCES OV101 SHOWS COMPARABLE PK PROFILE IN PHASE 1 STUDY OF ADOLESCENT PATIENTS AND AMENDS PHASE 2 STARS CLINICAL TRIAL PROTOCOL TO INCLUDE ADOLESCENTS

BRIEF-Ovid Therapeutics Q3 loss per share $0.38

* Ovid Therapeutics reports third quarter 2017 financial results and corporate progress

BRIEF-Ovid Therapeutics announces first patient randomized in phase 1b/2a clinical trial of TAK-935

* Ovid Therapeutics announces first patient randomized in phase 1b/2a clinical trial of TAK-935/OV935 in adults with rare epilepsies Source text for Eikon: Further company coverage:

BRIEF-Ovid Therapeutics Q2 loss per share $0.57

* Ovid Therapeutics reports second quarter 2017 financial results and corporate progress

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up